AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The first half of fiscal 2016 has been fueled by the progress made in the clincal trials required to get full marketing approval as a biological in both the US and Europe. Key results are due in both set of trials in the forthcoming six months. Meanwhile, investment in marketing of Pollinex Quattro in Europe to expand market share ahead of full marketing approval has borne fruit in the first half. The company is well funded to deliver on its strategy with its short-course allergy vaccines expected to enter the market as a disruptive technology in 2019.
